Ganaxolone

(Ztalmy®)

Ztalmy®

Drug updated on 7/7/2023

Dosage FormSuspension (oral; 50 mg/mL)
Drug ClassModulators
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older.

Product Monograph / Prescribing Information

Document TitleYearSource
Ztalmy (ganaxolone) Prescribing Information. 2022Marinus Pharmaceuticals, Inc., Radnor, PA

Systematic Reviews / Meta-Analyses